← Back to patent-cliff list
NVG-291
Tier C — Watch / tradeNVG-291
NervGen Pharma Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Chondroitin sulfate proteoglycans
Indications (approved)：Cardiac and vascular disorders, Spinal cord injury, Alzheimer's disease, Multiple sclerosis
Regional status
US
Phase III
2026-09-23
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NVG-291?
Approved indications include: Cardiac and vascular disorders, Spinal cord injury, Alzheimer's disease, Multiple sclerosis.
When does the NVG-291 patent expire?
No public expiry year is available for NVG-291 yet; this page updates once verified.
How do I get a quote for NVG-291 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28